Search

Your search keyword '"Weller, I"' showing total 319 results

Search Constraints

Start Over You searched for: Author "Weller, I" Remove constraint Author: "Weller, I" Language english Remove constraint Language: english
319 results on '"Weller, I"'

Search Results

1. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

2. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

3. Autoinjector preference among patients with multiple sclerosis: results from a national survey

4. The cost‐effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa

5. Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b

28. High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy

29. Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes

36. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee

37. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

38. Combination antiretroviral therapy and the risk of myocardial infarction

39. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

40. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery

41. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

42. The incidence of AIDS-defining illnesses at a current CD4 count ≥200 cells/μL in the post-combination antiretroviral therapy era

43. Lack of association between mitochondrial DNA polymorphisms and didexoxynucleoside-induced hyperlactataemia in black-African, HIV-1-infected patients

44. CD4 cell count and the risk of AIDS or death in HIV-Infected adults oncombination antiretroviral therapy with a suppressed viral load: a longitudinalcohort study from COHERE

45. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

46. Risk of triple-class virological failure in children with HIV: a retrospective cohort study

47. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: The STALWART study

48. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

49. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study

50. Response to combination antiretroviral therapy: Variation by age

Catalog

Books, media, physical & digital resources